Pharmacokinetic properties of hemoglobin vesicles as a substitute for red blood cells

References

• Abe, H., Ikebuchi, K., Hirayama, J., Fujihara, M., Takeoka, S., Sakai, H., et al. (2001). Virus inactivation in hemoglobin solution by heat treatment. Artif Cells Blood Substit Immobil Biotechnol 29:381–388.
   PubMed Web of Science ®Google Scholar
• Abernethy, D. R., Greenblatt, D. J., Divoll, M., Harmatz, J. S., Shader, R. I. (1981). Alterations in drug distribution and clearance due to obesity. J Pharmacol Exp Ther 217:681–685.
   PubMed Web of Science ®Google Scholar
• Awasthi, V., Yee, S. H., Jerabek, P., Goins, B., Phillips, W. T. (2007). Cerebral oxygen delivery by liposome-encapsulated hemoglobin: a positron-emission tomographic evaluation in a rat model of hemorrhagic shock. J Appl Physiol 103:28–38.
   PubMed Web of Science ®Google Scholar
• Balla, J., Vercellotti, G. M., Jeney, V., Yachie, A., Varga, Z., et al. (2005). Heme, heme oxygenase, and ferritin in vascular endothelial cell injury. Mol Nutr Food Res 49:1030–1043.
   PubMed Web of Science ®Google Scholar
• Bekersky, I., Fielding, R. M., Dressler, D. E., Kline, S., Buell, D. N., Walsh, T. J. (2001). Pharmacokinetics, excretion, and mass balance of 14C after administration of 14C-cholesterol-labeled AmBisome to healthy volunteers. J Clin Pharmacol 41:963–971.
   PubMed Web of Science ®Google Scholar
• Burhop, K., Gordon, D., Estep, T. (2004). Review of hemoglobin-induced myocardial lesions. Artif Cells Blood Substit Immobil Biotechnol 32:353–374.
   PubMed Web of Science ®Google Scholar
• Chang, T. M., Powanda, D., Yu, W. P. (2003). Analysis of polyethylene-glycol-polylactide nano-dimension artificial red blood cells in maintaining systemic hemoglobin levels and prevention of methemoglobin formation. Artif Cells Blood Substit Immobil Biotechnol 31:231–247.
   PubMed Web of Science ®Google Scholar
• Chen, J. Y., Scerbo, M., Kramer, G. (2009). A review of blood substitutes: examining the history, clinical trial results, and ethics of hemoglobin-based oxygen carriers. Clinics (Sao Paulo) 64:803–813.
   PubMed Web of Science ®Google Scholar
• Creteur, J., Vincent, J. L. (2003) Hemoglobin solutions. Crit Care Med 31:S698–S707
   PubMed Web of Science ®Google Scholar
• Dams, E. T., Laverman, P., Oyen, W. J., Storm, G., Scherphof, G. L., van Der Meer, J. W., et al. (2000). Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther 292:1071–1079.
   PubMed Web of Science ®Google Scholar
• Gabizon, A., Shmeeda, H., Barenholz, Y. (2003). Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 42:419–436.
   PubMed Web of Science ®Google Scholar
• Goins, B., Klipper, R., Sanders, J., Cliff, R. O., Rudolph, A. S., Phillips, W. T. (1995). Physiological responses, organ distribution, and circulation kinetics in anesthetized rats after hypovolemic exchange transfusion with technetium-99m-labeled liposome-encapsulated hemoglobin. Shock 4:121–130.
   PubMed Web of Science ®Google Scholar
• Grone, E. F., Grone, H. J. (2008). Does hyperlipidemia injure the kidney? Nat Clin Pract Nephrol 4:424–425.
   PubMedGoogle Scholar
• Hughes, G. S., Jr., Francome, S. F., Antal, E. J., Adams, W. J., Locker, P. K., Yancey, E. P., et al. (1995). Hematologic effects of a novel hemoglobin-based oxygen carrier in normal male and female subjects. J Lab Clin Med 126:444–451.
   PubMed Web of Science ®Google Scholar
• Ishida, T., Ichihara, M., Wang, X., Kiwada, H. (2006a). Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J Contr Rel 115:243–250.
   PubMed Web of Science ®Google Scholar
• Ishida, T., Ichihara, M., Wang, X., Yamamoto, K., Kimura, J., Majima, E., et al. (2006b). Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Contr Rel 112:15–25.
   PubMed Web of Science ®Google Scholar
• Ishida, T., Kashima, S., Kiwada, H. (2008). The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats. J Contr Rel 126:162–165.
   PubMed Web of Science ®Google Scholar
• Ishida, T., Maeda, R., Ichihara, M., Irimura, K., Kiwada, H. (2003a). Accelerated clearance of PEGylated liposomes in rats after repeated injections. J Contr Rel 88:35–42.
   PubMed Web of Science ®Google Scholar
• Ishida, T., Masuda, K., Ichikawa, T., Ichihara, M., Irimura, K., Kiwada, H. (2003b). Accelerated clearance of a second injection of PEGylated liposomes in mice. Int J Pharm 255:167–174.
   PubMed Web of Science ®Google Scholar
• Izumi, T., Enomoto, S., Hosiyama, K., Sasahara, K., Shibukawa, A., Nakagawa, T., et al. (1996). Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 277:1630–1641.
   PubMed Web of Science ®Google Scholar
• Jahr, J. S., Moallempour, M., Lim, J. C. (2008). HBOC-201, hemoglobin glutamer-250 (bovine), Hemopure (Biopure Corporation). Exp Opin Biol Ther 8:1425–1433.
   PubMed Web of Science ®Google Scholar
• Jahr, J. S., Walker, V., Manoochehri, K. (2007). Blood substitutes as pharmacotherapies in clinical practice. Curr Opin Anaesthesiol 20:325–330.
   PubMed Web of Science ®Google Scholar
• Kadowaki, D., Anraku, M., Tasaki, Y., Kitamura, K., Wakamatsu, S., Tomita, K., et al. (2007). Effect of olmesartan on oxidative stress in hemodialysis patients. Hypertens Res 30:395–402.
   PubMed Web of Science ®Google Scholar
• Kiwada, H., Matsuo, H., Harashima, H. (1998). Identification of proteins mediating clearance of liposomes using a liver perfusion system. Adv Drug Deliv Rev 32:61–79.
   PubMed Web of Science ®Google Scholar
• Kristiansen, M., Graversen, J. H., Jacobsen, C., Sonne, O., Hoffman, H. J., Law, S. K., et al. (2001). Identification of the haemoglobin scavenger receptor. Nature 409:198–201.
   PubMed Web of Science ®Google Scholar
• Kuipers, F., Spanjer, H. H., Havinga, R., Scherphof, G. L., Vonk, R. J. (1986). Lipoproteins and liposomes as in vivo cholesterol vehicles in the rat: preferential use of cholesterol carried by small unilamellar liposomes for the formation of muricholic acids. Biochim Biophys Acta 876:559–566.
   PubMed Web of Science ®Google Scholar
• Lee, J., Yoon, S., Nho, K. (2006). Pharmacokinetics of 125I-radiolabelled PEG-hemoglobin SB1. Artif Cells Blood Substit Immobil Biotechnol 34:277–292.
   PubMed Web of Science ®Google Scholar
• Lok, C. (2001). Blood product from cattle wins approval for use in humans. Nature 410:855.
   PubMed Web of Science ®Google Scholar
• Natanson, C., Kern, S. J., Lurie, P., Banks, S. M., Wolfe, S. M. (2008). Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA 299:2304–2312.
   PubMed Web of Science ®Google Scholar
• Noble, C. O., Krauze, M. T., Drummond, D. C., Yamashita, Y., Saito, R., Berger, M. S., et al. (2006). Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res 66:2801–2806.
   PubMed Web of Science ®Google Scholar
• Nose, Y. (2004). Is there a role for blood substitutes in civilian medicine: a drug for emergency shock cases? Artif Org 28:807–812.
   PubMed Web of Science ®Google Scholar
• Okamura, Y, Takeoka, S, Eto, K, Maekawa, I, Fujie, T, Maruyama, H, et al. (2009). Development of fibrinogen gamma-chain peptide-coated, adenosine diphosphate-encapsulated liposomes as a synthetic platelet substitute. J Thromb Haemost 7:470–477.
   PubMed Web of Science ®Google Scholar
• Okumura, H., Katoh, M., Minami, K., Nakajima, M., Yokoi, T. (2007). Change of drug excretory pathway by CCl4-induced liver dysfunction in rat. Biochem Pharmacol 74:488–495.
   PubMed Web of Science ®Google Scholar
• Pape, A., Habler, O. (2007). Alternatives to allogeneic blood transfusions. Best Pract Res Clin Anaesthesiol 21:221–239.
   PubMedGoogle Scholar
• Parry, E. (1988). Blood substitutes: historical perspective. In: Lowe, K. C. (Ed.), Blood substitute: preparation, phisiology, and medical applications ( pp. 17–49). New York: Ellis Horwood.
   Google Scholar
• Plock, J. A., Rafatmehr, N., Sinovcic, D., Schnider, J., Sakai, H., Tsuchida, E., et al. (2009). Hemoglobin vesicles improve wound healing and tissue survival in critically ischemic skin in mice. Am J Physiol Heart Circ Physiol 297:H905–H910
   PubMed Web of Science ®Google Scholar
• Sakai, H., Horinouchi, H., Tomiyama, K., Ikeda, E., Takeoka, S., Kobayashi, K., et al. (2001) Hemoglobin-vesicles as oxygen carriers: influence on phagocytic activity and histopathological changes in reticuloendothelial system. Am J Pathol 159:1079–1088.
   PubMed Web of Science ®Google Scholar
• Sakai, H., Masada, Y., Horinouchi, H., Ikeda, E., Sou, K., Takeoka, S., et al. (2004a). Physiological capacity of the reticuloendothelial system for the degradation of hemoglobin vesicles (artificial oxygen carriers) after massive intravenous doses by daily repeated infusions for 14 days. J Pharmacol Exp Ther 311:874–884.
   PubMed Web of Science ®Google Scholar
• Sakai, H., Masada, Y., Horinouchi, H., Yamamoto, M., Ikeda, E., Takeoka, S., et al. (2004b). Hemoglobin-vesicles suspended in recombinant human serum albumin for resuscitation from hemorrhagic shock in anesthetized rats. Crit Care Med 32:539–545.
   PubMed Web of Science ®Google Scholar
• Sakai, H., Seishi, Y., Obata, Y., Takeoka, S., Horinouichi, H., Tsuchida, E., et al. (2009). Fluid resuscitation with artificial oxygen carriers in hemorrhaged rats: profiles of hemoglobin-vesicle degradation and hematopoiesis for 14 days. Shock 31:192–200.
   PubMed Web of Science ®Google Scholar
• Sakai, H., Sou, K., Horinouchi, H., Kobayashi, K., Tsuchida, E. (2008). Haemoglobin-vesicles as artificial oxygen carriers: present situation and future visions. J Intern Med 263:4–15.
   PubMed Web of Science ®Google Scholar
• Sakai, H., Takeoka, S., Yokohama, H., Seino, Y., Nishide, H., Tsuchida, E. (1993). Purification of concentrated hemoglobin using organic solvent and heat treatment. Prot Expr Purif 4:563–569.
   PubMed Web of Science ®Google Scholar
• Sakai, H., Tomiyama, K. I., Sou, K., Takeoka, S., Tsuchida, E. (2000). Poly(ethylene glycol)-conjugation and deoxygenation enable long-term preservation of hemoglobin-vesicles as oxygen carriers in a liquid state. Bioconjug Chem 11:425–432.
   PubMed Web of Science ®Google Scholar
• Sakai, H., Tsuchida, E. (2007). Hemoglobin-vesicles for a transfusion alternative and targeted oxygen delivery. J Liposome Res 17:227–235.
   PubMed Web of Science ®Google Scholar
• Savitsky, J. P., Doczi, J., Black, J., Arnold, J. D. (1978). A clinical safety trial of stroma-free hemoglobin. Clin Pharmacol Ther 23:73–80.
   PubMed Web of Science ®Google Scholar
• Sehgal, L. R., Gould, S. A., Rosen, A. L., Sehgal, H. L., Moss, G. S. (1984). Polymerized pyridoxylated hemoglobin: a red cell substitute with normal oxygen capacity. Surgery 95:433–438.
   PubMed Web of Science ®Google Scholar
• Shimoishi, K., Anraku, M., Kitamura, K., Tasaki, Y., Taguchi, K., Hashimoto, M., et al. (2007). An oral adsorbent, AST-120, protects against the progression of oxidative stress by reducing the accumulation of indoxyl sulfate in the systemic circulation in renal failure. Pharm Res 24:1283–1289.
   PubMed Web of Science ®Google Scholar
• Smani, Y. (2008). Hemospan: a hemoglobin-based oxygen carrier for potential use as a blood substitute and for the potential treatment of critical limb ischemia. Curr Opin Investig Drugs 9:1009–1019.
   PubMed Web of Science ®Google Scholar
• Sou, K., Endo, T., Takeoka, S., Tsuchida, E. (2000). Poly(ethylene glycol)-modification of the phospholipid vesicles by using the spontaneous incorporation of poly(ethylene glycol)-lipid into the vesicles. Bioconjug Chem 11:372–379.
   PubMed Web of Science ®Google Scholar
• Sou, K., Goins, B., Takeoka, S., Tsuchida, E., Phillips, W. T. (2007). Selective uptake of surface-modified phospholipid vesicles by bone marrow macrophages in vivo. Biomaterials 28:2655–2666.
   PubMed Web of Science ®Google Scholar
• Sou, K., Klipper, R., Goins, B., Tsuchida, E., Phillips, W. T. (2005). Circulation kinetics and organ distribution of Hb-vesicles developed as a red blood cell substitute. J Pharmacol Exp Ther 312:702–709.
   PubMed Web of Science ®Google Scholar
• Spahn, D. R., Kocian, R. (2003). The place of artificial oxygen carriers in reducing allogeneic blood transfusions and augmenting tissue oxygenation. Can J Anaesth 50:S41–S47
   PubMed Web of Science ®Google Scholar
• Stowell, C. P. (2005). What happened to blood substitutes? Transfus Clin Biol 12:374–379.
   PubMed Web of Science ®Google Scholar
• Taguchi, K., Iwao, Y., Watanabe, H., Kadowaki, D., Sakai, H., Kobayashi, K., et al. (2011a). Repeated injection of high doses of hemoglobin encapsulated liposomes (hemoglobin-vesicles) induces accelerated blood clearance in a hemorrhagic shock rat model. Drug Metab Dispos 39:484–489.
   PubMed Web of Science ®Google Scholar
• Taguchi, K., Maruyama, T., Iwao, Y., Sakai, H., Kobayashi, K., Horinouchi, H., et al. (2009a). Pharmacokinetics of single and repeated injection of hemoglobin-vesicles in hemorrhagic shock rat model. J Contr Rel 136:232–239.
   PubMed Web of Science ®Google Scholar
• Taguchi, K., Miyasato, M., Ujihira, H., Watanabe, H., Kadowaki, D., Sakai, H., et al. (2010). Hepatically-metabolized and -excreted artificial oxygen carrier, hemoglobin-vesicles, can be safely used under conditions of hepatic impairment. Toxicol Appl Pharmacol 248:234–241.
   PubMed Web of Science ®Google Scholar
• Taguchi, K., Miyasato, M., Watanabe, H., Sakai, H., Tsuchida, E., Horinouchi, H., et al. (2011b). Alteration in the pharmacokinetics of hemoglobin-vesicles in a rat model of chronic liver cirrhosis is associated with Kupffer cell phagocyte activity. J Pharm Sci 100:775–783.
   PubMed Web of Science ®Google Scholar
• Taguchi, K., Urata, Y., Anraku, M., Maruyama, T., Watanabe, H., Sakai, H., et al. (2009b). Pharmacokinetic study of enclosed hemoglobin and outer lipid component after the administration of hemoglobin vesicles as an artificial oxygen carrier. Drug Metab Dispos 37:1456–1463.
   PubMed Web of Science ®Google Scholar
• Taguchi, K., Urata, Y., Anraku, M., Watanabe, H., Kadowaki, D., Sakai, H., et al. (2009c). Hemoglobin vesicles, polyethylene glycol (PEG)ylated liposomes developed as a red blood cell substitute, do not induce the accelerated blood clearance phenomenon in mice. Drug Metab Dispos 37:2197–2203.
   PubMed Web of Science ®Google Scholar
• Takaori, M. (2005). Approach to clinical trial considering medical ethics and efficacy for HbV, liposome encapsulated hemoglobin vesicle. Artif Cells Blood Substit Immobil Biotechnol 33:65–73.
   PubMed Web of Science ®Google Scholar
• Terajima, K., Tsueshita, T., Sakamoto, A., Ogawa, R. (2006). Fluid resuscitation with hemoglobin vesicles in a rabbit model of acute hemorrhagic shock. Shock 25:184–189.
   PubMed Web of Science ®Google Scholar
• Turck, D., Schwarz, A., Hoffler, D., Narjes, H. H., Nehmiz, G., Heinzel, G. (1996). Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: a comparison with healthy volunteers. Eur J Clin Pharmacol 51:309–313.
   PubMed Web of Science ®Google Scholar
• Walsh, T. J., Yeldandi, V., McEvoy, M., Gonzalez, C., Chanock, S., Freifeld, A., et al. (1998). Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother 42:2391–2398.
   PubMed Web of Science ®Google Scholar
• Wang, X., Ishida, T., Kiwada, H. (2007). Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Contr Rel 119:236–244.
   PubMed Web of Science ®Google Scholar
• Yamamoto, M., Izumi, Y., Horinouchi, H., Teramura, Y., Sakai, H., Kohno, M., et al. (2009). Systemic administration of hemoglobin vesicle elevates tumor tissue oxygen tension and modifies tumor response to irradiation. J Surg Res 151:48–54.
   PubMed Web of Science ®Google Scholar
• Yamazaki, M., Aeba, R., Yozu, R., Kobayashi, K. (2006). Use of hemoglobin vesicles during cardiopulmonary bypass priming prevents neurocognitive decline in rats. Circulation 114:I220–I225
   PubMed Web of Science ®Google Scholar
• Zweifach, B. W., Benacerraf, B. (1958). Effect of hemorrhagic shock on the phagocytic function of Kupffer cells. Circ Res 6:83–87.
   PubMed Web of Science ®Google Scholar